1 Original Research Article

- 2 Title Page
- 3 Title
- 4 Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
- 5

6 Authors

- 7 Malgorzata Mikulska^{1,2*}, Laura Ambra Nicolini², Alessio Signori³, Antonio Di Biagio^{1,2},
- 8 Chiara Sepulcri¹, Chiara Russo¹, Silvia Dettori¹, arco Berruti¹, Maria Pia Sormani³, Daniele
- 9 Roberto Giacobbe ^{1,2}, Antonio Vena ², Andrea De Maria ^{1,2}, Chiara Dentone ², Lucia
- 10 Taramasso², Michele Mirabella^{1,2}, Laura Magnasco^{1,2}, Sara Mora⁴, Emanuele Delfino²,
- 11 Federica Toscanini², Elisa Balletto^{1,2}, Anna Ida Alessandrini², Federico Baldi¹, Federica
- 12 Briano¹, Marco Camera², Ferdinando Dodi², Antonio Ferrazin², Laura Labate¹, Giovanni
- 13 Mazzarello², Rachele Pincino¹, Federica Portunato^{2,5}, Stefania Tutino¹, Emanuela Barisione
- ⁶, Bianca Bruzzone⁷, Andrea Orsi^{7,8}, Eva Schenone², Nirmala Rosseti², Elisabetta Sasso⁹,
- 15 Giorgio Da Rin¹⁰, Paolo Pelosi^{11,12}, Sabrina Beltramini⁹, Mauro Giacomini⁴, Giancarlo
- 16 Icardi^{7,8}, Angelo Gratarola¹³, Matteo Bassetti^{1,2}
- 17

18 Affiliations

- 19 1. Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of
- 20 Genoa, Genoa, Italy
- 21 2. Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 3. Section of Biostatistics, Department of Health Sciences, University of Genova, Genova,
 Italy
- 4. Department of Informatics, Bioengineering, Robotics and System Engineering, University
- 25 of Genoa, Genoa, Italy
- 26 5 Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Napoli

- 27 6. Interventional Pulmonology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 28 7. Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- 29 8. Department of Health Sciences, University of Genoa
- 30 9. Pharmacy Complex Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 31 10. Medicine Laboratory, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 32 11. Department of Surgical Sciences and Integrated Diagnostics, University of Genova,
- 33 Genova, Italy
- 34 12. Anesthesia and Intensive Care, San Martino Policlinico Hospital, IRCCS for Oncology
- 35 and Neurosciences, Genoa, Italy
- 36 13. Department of Emergency and Urgency, San Martino Policlinico Hospital, IRCCS for
- 37 Oncology and Neurosciences, Genoa, Italy
- 38

39 ***Corresponding author**

- 40 <u>m.mikulska@unige.it (MM)</u>
- 41

42 Abstract

43 Introduction

44 Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to severe immune

45 response. Treatment targeting this immune response might be beneficial but there is limited

46 evidence on its efficacy.

47 The aim of this study was to determine if early treatment of patients with COVID-19

48 pneumonia with tocilizumab and/or steroids was associated with better outcome.

49 Methods

50 This observational single-center study included patients with COVID-19 pneumonia who 51 were not intubated and received either standard of care (SOC, controls) or SOC plus early 52 (within 3 days from hospital admission) anti-inflammatory treatment. SOC consisted of 53 hydroxychloroquine 400mg bid plus, in those admitted before March 24th, also 54 darunavir/ritonavir. Anti-inflammatory treatment consisted of either tocilizumab (8mg/kg 55 intravenously or 162mg subcutaneously) or methylprednisolone 1 mg/kg for 5 days or both. 56 Failure was defined as intubation or death, and the endpoints were failure-free survival 57 (primary endpoint) and overall survival (secondary) at day 30. Difference between the groups 58 was estimated as Hazard Ratio by a propensity score weighted Cox regression analysis 59 (HR_{OW}) .

60 Results

Overall, 196 adults were included in the analyses. They were mainly male (67.4%), with comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9 years (range, 30-100) and median PaO_2/FiO_2 200 mmHg (IQR 133-289). Among them, 130 received early anti-inflammatory treatment with: tocilizumab (n=29, 22.3%), methylprednisolone (n=45, 34.6%), or both (n=56, 43.1%). The adjusted failure-free survival among tocilizumab/methylprednisolone/SOC treated patients vs. SOC was 80.8% (95%CI, 72.8-86.7) vs. 64.1% (95%CI, 51.3-74.0), HR_{OW} 0.48, 95%CI, 0.23-0.99; p=0.049. The

- 68 overall survival among tocilizumab/methylprednisolone/SOC patients vs. SOC was 85.9%
- 69 (95%CI, 80.7-92.6) vs. 71.9% (95%CI, 46-73), HR_{OW} 0.41, 95%CI: 0.19-0.89, p=0.025.
- 70 Conclusion
- 71 Early adjunctive treatment with tocilizumab, methylprednisolone or both may improve
- 72 outcomes in non-intubated patients with COVID-19 pneumonia.
- 73
- 74
- 75 Keywords: Tocilizumab, interleukin-6, SARS-CoV-2, steroids, pneumonia, ARDS, COVID-
- 76 19, treatment.
- 77

78 Introduction

79 Pandemic coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 coronavirus has 80 recently emerged [1]. Although most of the infected patients will remain asymptomatic or 81 develop mild symptoms, up to 20% may develop severe disease with pneumonia and 82 respiratory failure [2]. Oxygen administration is the cornerstone of supportive treatment and 83 is required in approximately 15% of cases, while invasive mechanical ventilation is necessary 84 in up to 5-7% of severe cases [3-5]. Since mortality in patients with invasive ventilation can 85 be very high, halting the progression from moderate to severe respiratory failure should 86 reduce the mortality in COVID-19 [6].

87 At the beginning of COVID-19 pandemics, based on the experience with previous studies in 88 viral pneumonia, including SARS-CoV and MERS, the use of steroids was discouraged, 89 mainly due to undocumented benefit and fearing potential increase in viral proliferation and 90 side effects [7, 8]. However, with the increasing knowledge about COVID-19, a biphasic 91 model of the disease has been proposed [9, 10]. According to this model, the first phase is 92 caused directly by viral replication, while in the second phase, the symptoms and respiratory 93 failure are due to inflammatory response, and could be treated with agents which reduce 94 inflammation, such as corticosteroids, or inhibitors of pro-inflammatory interleukins and 95 Janus kinase (JAK) [9-11].

96 Indeed, some real life experiences in COVID-19 patients showed that the use of anti-97 inflammatory treatments might be beneficial [12]. In fact, short-term steroid therapy was 98 associated with lower mortality in 201 patients with acute respiratory distress syndrome 99 (ARDS) [13]. Additionally, following the data on presence of inflammatory cytokine storm in 100 severe COVID-19, tocilizumab use has been advocated. This monoclonal antibody, which 101 binds to interleukin 6 (IL-6) receptor and blocks the IL-6 mediated inflammatory response, is 102 approved for treatment of rheumatologic disorders and cytokine-release syndrome associated

with Chimeric Antigen Receptor T-cell (CAR-T) administration. It was reported to reduce
COVID-19-associated inflammation, and was approved in China for this indication [12, 14].
Based on the first evidences, we formulated the hypothesis of potential benefit of antiinflammatory treatment, and progressively modified our therapeutic approach to COVID-19.
We started using tocilizumab in patients with respiratory failure, and subsequently, we
introduced into our protocol early administration of methylprednisolone treatment, followed
in more severe cases by the administration of tocilizumab.

We hypothesized that outcomes such as no need for intubation and survival of patients with severe COVID-19 pneumonia in whom tocilizumab and/or methylprednisolone were administered in addition to standard of care (SOC) could be better than in those who received only SOC.

114

115 **Patients and methods**

116 Setting and patients

In this observational single-center study, adult patients admitted to the San Martino University Hospital, Genova, Italy, for COVID-19 pneumonia were included as cases if treated with tocilizumab and/or methylprednisolone, not intubated, not treated with remdesivir and not pregnant. The outcomes of patients treated with tocilizumab/methylprednisolone were compared to data from consecutive patients admitted to our hospital for COVID-19 pneumonia who received only SOC, mainly because they were admitted before the routine use of tocilizumab/methylprednisolone (control group).

All patients provided an informed consent for treatment with off label agents according to the local protocol approved by Hospital Authorities, for data collection and for participation in the study. The study was carried out in accordance with the principles of the Declaration of Helsinki and approved by the Regional Ethic Committee (N. CER Liguria 114/2020-ID 10420).

129 Data collection and definitions

Data were collected from hospital information system by a standard based automatic procedure and stored in an online database with pseudo-anonymization features suitable for secondary use of clinical data [15]. Controls were identified through this prospectively collected database of hospital-admitted COVID-19 patients.

Patients who had any of the following features at the time of, or after, admission were classified as having severe pneumonia: (1) respiratory distress (\geq 30 breaths per min); or (2) oxygen saturation at rest \leq 93%; or (3) ratio of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air (PaO₂/FiO₂) \leq 300 mm Hg; or (4) severe disease complications (e.g., respiratory failure, requirement of mechanical ventilation, septic shock, or non-respiratory organ failure) [7, 14, 15].

140 Systemic inflammation was defined as presence at baseline of one of the following: fever >

141 38°C, C-reactive protein (CRP) 10 times above the upper limit of normal (ULN) of 5 mg/dl,

ferritin 2 times above the ULN (400 μ g/L), or IL-6 10 times above the ULN of 3.4 ng/L. The first results obtained at hospital admission, and in any case not later than within day 3 of admission were considered.

Adverse events possibly or probably related to steroid and tocilizumab treatment, such as neutropenia, anemia, thrombocytopenia, increase in alanine aminotransferase (ALT) levels, (UNL < 40 U/L), microbiologically documented infections and allergic reactions were evaluated for both treated patients and controls. Adverse events were collected up to the last available follow up from starting of tocilizumab and/or methylprednisolone in treatment group and from hospital admission in the control group. The common terminology criteria for adverse event (CTCAE) version 5.0 was used.

152 Standard of care and treatment procedures

153 The diagnosis of COVID-19 was made with a positive RT-PCR assay performed on nasal 154 swab or broncoalveolar lavage fluid according to World Health Organization interim guidance

[16]. Patients received treatment with oral hydroxychloroquine 400mg bid, unless glucose-6phosphate dehydrogenase deficient. Until March 24th, darunavir/ritonavir 800/100 qd was also administered [17]. Thereafter, the protocol was amended and darunavir/ritonavir was withdrawn [18]. Short-term antibiotic coverage was prescribed at admission. Low-molecularweight heparin prophylaxis was administered unless contraindicated. These treatments were defined as SOC.

Since March 11th, we started adding tocilizumab to SOC in case of severe COVID-19 161 162 pneumonia and systemic inflammation. Tocilizumab was administered intravenously at the 163 dose of 8mg/kg (maximum 800mg), with the possibility of repeating the dose after 24 hours if 164 no response was obtained. Due to a temporary shortage of intravenous formulation, the 165 available subcutaneous formulation (162 mg) was administered. Following an internal review 166 of risks and benefits of steroid treatment in patients with severe COVID-19, since March 16th 167 methylprednisolone (1mg/kg for 5 days intravenously, then 0.5mg/kg for 5 days) was 168 included in the protocol. Tocilizumab was added in case of systemic inflammation or rapid 169 respiratory function deterioration.

170 Statistical analysis

No sample-size calculations were performed. The primary end point was time to failure,
defined as intubation and mechanical ventilation or death, whichever occurred first, within 30
days from the hospital admission.

The secondary endpoint was overall survival (OS). Time was calculated from time of hospitalization for the comparison between tocilizumab/methylprednisolone/SOC and SOC patients and from the date of starting anti-inflammation treatment for the comparison among treatment groups.

The landmark analysis was applied in order to minimize the potential immortal time bias that can arise in non-randomized studies and is related to the fact that patients treated after a longer time from admission must have not experienced the event up to that time, and that

patients with a very early event (e.g. death) were more likely assigned to the untreated group. This is a conservative analysis which reduced the risk that the treatment choice was motivated by the patient's disease course. Therefore, day 3 from hospital admission was set as a landmark time point: those who died, were intubated or discharged from the hospital before day 3 were excluded, while patients were included in the tocilizumab/methylprednisolone treatment group if the treatment was started within 3 days from hospital admission (see Figure 1).

188 To minimize baseline differences between treated and untreated patients a propensity score-189 based analysis was performed. Propensity score (PS) was derived by a logistic regression 190 model including the following baseline variables: age, gender, presence of comorbidities and 191 week of treatment start, ratio of partial pressure of arterial oxygen to fractional concentration 192 of oxygen inspired air (PaO₂/FiO₂), non-invasive ventilation (NIV), time from symptoms 193 onset to hospital admission, IL-6, ferritin, C-reactive protein (CRP) and d-dimer serum levels. 194 Positivity assumption of PS was checked after the calculation. For each patient, the overlap 195 weight (OW) based on PS was calculated [19]. To assess the balance of covariate distribution 196 between the two groups, Cohen's standardized mean differences were calculated between the 197 two groups in the original samples and after weighting. An absolute value of difference < 0.10198 was considered an acceptable balance.

The OW-weighted Cox proportional hazard regression model was used to calculate the
 adjusted hazard-ratio (HR_{OW}) of tocilizumab/methylprednisolone/SOC vs SOC patients.

Weighted cumulative probability of failure or death was calculated by mean of Kaplan-Meier(KM) survival curves.

To define risk factors associated with outcomes and to compare the three treatment groups, adjusted HRs were estimated by a multivariable Cox proportional hazard regression model. The same baseline variables used in the calculation of PS were considered for the multivariable analysis. To avoid overfitting, only those characteristics who showed a p-value

≤ 0.15 at univariable analysis and after inclusion in the multivariable model were considered,
with age and gender forced into the model. For a better interpretation and to avoid the
influence of outliers on estimation, the IL-6, ferritin, CRP and d-dimer were log-transformed
before the analysis due to the highly skewed distribution. All results were reported as HR with
95% confidence interval (95%CI).
A subgroup analysis was performed to assess if the treatment effect of tocilizumab versus
methylprednisolone on primary outcome was different between subgroups defined according

214 to categorized baseline variables. An interaction test was used to assess a different treatment 215 effect in subgroups.

216 The sensitivity analysis pre-planned, and the comparison between was 217 tocilizumab/methylprednisolone/SOC and SOC patients was reassessed excluding from the 218 SOC group the patients that received tocilizumab or methylprednisolone after 3 days from 219 hospitalization. The PS and OW were recalculated.

- 220 P was considered significant if ≤ 0.05 . Stata (v.16; StataCorp.) was used for the computation.
- 221

222 Results

223 Patients

Overall, 215 patients were evaluated: 135 (62.8%) received tocilizumab/methylprednisolone within 3 days from hospitalization, 20 (12.9%) were treated after 3 days from hospitalization and were included in the SOC group, and 60 (38.7%) patients received only SOC. After excluding the patients who were discharged or developed a failure event (intubation or death) before the day 3 set for landmark analysis, 196 patients were included (130 tocilizumab/methylprednisolone/SOC and 66 SOC patients) (Figure 1). Patients were mainly male (67.4%), with a median age of 67.9 years (range, 30-100), and

- 231 most of them (78.1%) had comorbidities (Table 1). The median PaO_2/FiO_2 was 200 mmHg
- 232 (interquartile range, IQR 133-289), and 164 (83.7%) had severe pneumonia (PaO_2/FiO_2

- 233 <300mmHg). The median time from the onset of symptoms to anti-inflammatory treatment in
- 234 130 patients was 8 days, IQR: 9-15; range 5-23.
- 235 <u>Failure rate</u>
- In univariable and multivariable analyses, older age, male gender, higher baseline inflammatory markers, especially IL-6, and $PaO_2/FiO_2 < 100$ mmHg were identified as risk
- factors for failure (Table 2).
- Differences between the two groups were consistently reduced after OW. OW weightedcharacteristics of two groups of patients are shown in Table 3.
- After a median follow-up of 49 days (range 4-70, IQR 30-56), 17 patients were intubated
- 242 (14/130 in tocilizumab/methylprednisolone/SOC and 3/66 in SOC group) and 36 died (14/130
- in tocilizumab/methylprednisolone/SOC and 22/66 in SOC group). Overall, 28 (21.5%)
- failure events were detected among tocilizumab/methylprednisolone/SOC patients and 25
 (37.9%) among SOC patients.
- 246 At day 14, the weighted failure-free survival was 86.5% (95%CI, 79.1-91.7) among
- tocilizumab/methylprednisolone/SOC and 75.8% (95%CI, 63.7-84.1) among SOC patients,
- 248 while at 30 days (primary endpoint) it was, respectively, 80.8% (95%CI, 72.8-86.7) and
- 249 64.1% (95%CI, 51.3-74.0) (Figure 2). The Cox regression analysis adjusted by OW weighted
- 250 propensity score estimated a significant effect of therapy in reducing the risk of failure (HR_{OW}
- 251 = 0.48 95%CI, 0.23-0.99; p=0.049).
- 252 <u>Tocilizumab/methylprednisolone treatment strategies</u>

Within the cohort of 130 treated patients, 45 (34.6%) received methylprednisolone, 29 (22.3%) tocilizumab and 56 (43.1%) combined therapy. Patients in combined treatment group were younger and with fewer comorbidities but with comparable inflammatory markers, the frequency of low PaO_2/FiO_2 and NIV (Table 4).

257 After a median follow-up of 53 days (range 4-70, interquartile range 33-57), 28 failures were 258 observed: in 14/45 (31.1%) patients receiving methylprednisolone, 6/29 (20.7%) tocilizumab 259 (1 subcutaneously and 5 intravenously) and 8/56 (14.3%) in combined treatment group. 260 At 14 days of follow-up from treatment start, the failure-free survival (Figure 3) was 80% 261 (95%CI, 65.1-89.1) in methylprednisolone group, 79.3% (95%CI, 59.6-90.1) in tocilizumab 262 group and 87.5% (95 CI, 75.6-93.8) in combined therapy group. No significant differences 263 between the three treatment groups were identified in a multivariable analysis adjusted for the 264 baseline risk factors (p for heterogeneity among treatment groups = 0.45) (Table 5). 265 Overall survival (OS) 266 A total of 45 deaths, 36 without a previous intubation, were registered during the follow-up: 267 23 (34.8%) were in the SOC and 22 (16.9%) in tocilizumab/methylprednisolone/SOC group. 268 At day 14 of follow-up, the OS was 92.7% (95%CI, 86.4-96.1) in 269 tocilizumab/methylprednisolone/SOC group and 78.2% (95%CI, 67.0-85.6) in SOC (Figure 270 4). At 30 days OS was, respectively, 85.9% (95%CI, 80.7-92.6) and 71.9% (95%CI, 59.9-271 80.8), with a significant better survival in tocilizumab/methylprednisolone/SOC patients in 272 OW analysis ($HR_{OW} = 0.41, 95\%$ CI: 0.19-0.89, p=0.025). 273 When considering only patients receiving tocilizumab/methylprednisolone/SOC, death 274 occurred in 13/45 (28.9%) patients receiving methylprednisolone, 4/29 (13.8%) tocilizumab 275 and 5/56 (8.9%) in those receiving combined therapy. At 30 days the OS was, 79.5% (95%CI, 276 64.2-88.8), 85.8% (95%CI, 66.5-94.4) and 90.9% (95%CI, 79.6-96.1) in patients treated, 277 respectively, with methylprednisolone, tocilizumab and combined therapy (adjusted p for 278 heterogeneity among treatments: 0.55). 279 Subgroup analyses

It was not possible to identify subgroups, based on demographic or clinical characteristics, with different benefits of tocilizumab versus methylprednisolone or tocilizumab versus combination therapy.

283 <u>Sensitivity analyses</u>

284	As a sensitivity analysis, we run the comparison between
285	tocilizumab/methylprednisolone/SOC and SOC patients excluding the 20 patients that
286	received tocilizumab/methylprednisolone treatment after 3 days from hospital admission (6
287	methylprednisolone, 8 tocilizumab and 6 both), and experienced 5 (25%) failures. The
288	weighted failure-free survival in the SOC group was now 72.5% (95%CI, 58.8-81.5) at 14
289	days and 67.1% (95%CI, 52.8-77.9) after 30 days. The OW weighted difference between
290	tocilizumab/methylprednisolone/SOC and SOC patients was amplified (HR $_{\rm OW}$ =0.39; 95%CI,
291	0.17-0.89; p=0.026).
292	Side effects

Among 155 patients who received tocilizumab/methylprednisolone/SOC at any time, 106 (68%) developed ALT increase (grade 1-2: 98/155, 63% and grade 3: 8/155, 5%): 32.4% of those who received methylprednisolone/SOC and 77% of those who received tocilizumab/SOC +/- methylprednisolone. Microbiologically documented infections were recorded in 12 (7.7%) patients: 10 bloodstream infections, 2 ventilator-associated pneumonias and 2 urinary tract infections. In tocilizumab/methylprednisolone/SOC group, grade 4 transient neutropenia and grade 2 maculopapular rash occurred in 1 patient each.

Among 60 SOC patients, grade 1-2 ALT increase occurred in 5 (8%) and 1 patient developed
 urinary tract infection.

302 There were no cases of significant decrease of hemoglobin or platelet levels.

303

304 Discussion

In this observational study in not intubated patients with mainly severe COVID-19 pneumonia, the early addition of tocilizumab and/or methylprednisolone to SOC resulted in adjusted failure-free survival of 86.5% and 80.8% at day 14 and 30, which was, respectively,

308 10.7% and 16.7% higher than in SOC patients.

309 Even though only the minority of patients develop the severe form of COVID-19 (14% in the 310 Chinese cohort of 72.314 patients), the outcomes in this group are poor, with 24.9% rate of 311 failure (intubation or death) reported in 173 patients with severe disease [2, 20]. The 312 observation that COVID-19-associated respiratory failure can be caused by cytokine storm 313 rather than viral progression is the rationale for administering anti-inflammatory treatments, 314 including tocilizumab [9, 10, 21]. The initial studies on tocilizumab in COVID-19 reported a 315 clinical benefit in retrospective cohorts of 21 and 15 patients with moderate to critical 316 COVID-19 pneumonia, in whom steroids were also administered [12, 22]. However, none of 317 studies reported and evaluated the impact of steroid co-administration, nor included a control 318 group which did not receive tocilizumab. Subsequently these treatments were recommended 319 by Chinese Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (version 6 320 and 7) [14]. However, considering the rapid widespread increase in severe cases of COVID-321 19 worldwide, the availability and the cost of anti-IL-6 treatment might limit its use. 322 Therefore, at the peak of COVID-19 epidemics in our city, we implemented the early use of 323 corticosteroids and the use of subcutaneous tocilizumab if intravenous formulation was not 324 readily available. We acknowledge that the benefit of subcutaneous formulation might be 325 lower and slower than in case of intravenous drug, but no standard intravenous dose for 326 COVID-19 has been established, as one study used 400 mg and the other the rage of doses 327 from 80 mg to 600 mg, irrespective of the patients' weight [12, 22].

The first study that reported the impact of steroid treatment in COVID-19, showed that it was administered to 30.8% of patients, mainly in case of more severe disease, and was associated with a significant reduction of the risk of death in patients with ARDS (HR=0.38) [13]. While other cohorts reported steroid use in approximately 44% of severely ill patients, they did not analyze their influence on outcome [20, 23]. Subsequently, an observational study reported a benefit of early administration of steroid therapy on composite outcome of ICU admission, mechanical ventilation or death at 14 days (34.9% vs. 54.3%) and overall survival (86.4% vs.

335 73.7%) [24]. In addition to these data, we were able to demonstrate that, after minimizing as 336 much as possible the differences between the groups through OW adjustment, the outcome of 337 patients was better in case of early treatment with tocilizumab and/or methylprednisolone. 338 Indeed, in SOC group the rate of failure at day 14 of 24.2% was very similar to what reported 339 in other cohorts with severe pneumonia (24.9%), while it was reduced to 13.5% in our 340 tocilizumab/methylprednisolone/SOC group [20]. Our data show that this benefit was also 341 present with month-long follow up (overall HR_{ow} of 0.48), which is important in establishing 342 long term prognosis of these patients. Moreover, the benefit of early 343 tocilizumab/methylprednisolone was also noted on overall survival, both at 14 and 30 days 344 (respectively, 92.7% vs. 78.2% and 85.9% vs. 71.9%). Compared to the study with steroid use 345 only, the 14-day survival was higher in our cohort, providing background for the hypothesis 346 that combined tocilizumab/steroid treatment might be warranted [24]. Finally, preliminary 347 results of the RECOVERY trial reported higher survival rate in patients with severe COVID-348 19 pneumonia treated with dexamethasone, although the detailed results are not available yet. 349 Interestingly, our observational study, which showed the effectives of early anti-inflammatory 350 treatment in a cohort of non-intubated patients with severe COVID-19 pneumonia, 351 documented that these patients were treated at a median time of 8 days after the onset of 352 symptoms, which is exactly the time of initial cytokine storm, and therefore might be optimal 353 for the effect of anti-inflammatory treatment.

Consistent with other studies, we identified older age, high IL-6 levels and poor respiratory function as independent predictors of failure, with possible impact also of CRP and d-dimer levels [25]. Possibly due to a limited sample size, we were unable to document which of three treatment groups provided most benefit, and if there were predictors of better response to tocilizumab/methylprednisolone compared to methylprednisolone alone in any subset of patients. However, the rate of failure-free survival was the highest in the combination treatment group. In addition, based on our sensitivity analyses, adding the anti-inflammatory

361 treatment later after hospital admission might still provide some clinical benefit. In fact, 362 including in the SOC group patients who received anti-inflammatory treatment later during 363 the infectious course possibly reduced the difference between the study arms, highlighting the 364 benefit of an early anti-inflammatory treatment.

365 The limitations of this study include the non-randomized design, yet the inclusion of 366 consecutive patients using the same SOC but not treated with tocilizumab or 367 methylprednisolone, and adjustment for the outcome-associated variables, allowed to notice 368 the improvement in patient outcomes. Nonetheless, it is possible that some benefit observed 369 was partially due to general improvements in patient clinical care that occur with time. 370 Additionally, this being a single-center experience might limit the applicability to other 371 settings, since our hospital managed to rapidly increase the capacity for hospitalization and 372 ventilation support, potentially improving general patient care. However, the adjustment for 373 the differences between patient groups through propensity score and conservative approach 374 with the use of landmark analysis were directly at minimizing the risk associated with an 375 absence of randomization. Finally, we believe that the rate of failure observed in this study of 376 at 14 days in those with severe COVID-19 treated with SOC and 7.3% 377 tocilizumab/methylprednisolone might help to better define the expected rate of response and 378 calculate the number of patients needed to include in the studies assessing various treatment 379 options.

380 Conclusion

In conclusion, the negative impact of immune response in COVID-19 might be mitigated by early administration of anti-inflammatory therapy with tocilizumab, methylprednisolone or both. Randomized studies are warranted to establish the best treatment options, their timing and limitations.

385

386 Acknowledgments

- 387 We would like to thank all the patients and the hospital staff, with particular mention of Mrs
- 388 Enrica Lombardi, who helped us to get through these difficult weeks.
- 389 This study was supported by the efforts of all members of GECOVID group.
- 390
- 391 Funding
- 392 No funding or sponsorship was received for this study or publication of this article.
- 393 Independently of the study, Roche provided intravenous tocilizumab free of charge for the
- 394 Ligurian Region during the first weeks of COVID-19 epidemics.
- 395 Some of the patients were included also in the observational Italian national AIFA study on
- 396 intravenous tocilizumab.

397 **References**

- Zhou F, Yu T, Du R, et al. (2020) Clinical course and risk factors for mortality of
 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
 395(10229): 1054-1062. 10.1016/s0140-6736(20)30566-3
- 401 [2] Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the
- 402 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314
- 403 Cases From the Chinese Center for Disease Control and Prevention. JAMA.404 10.1001/jama.2020.2648
- 405 [3] Grasselli G, Zangrillo A, Zanella A, et al. (2020) Baseline Characteristics and
- 406 Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy
- 407 Region, Italy. JAMA. 10.1001/jama.2020.5394
- 408 [4] Severe acute respiratory infections treatment centre: practical manual to set up and
- 409 manage a SARI treatment centre and SARI screening facility in health care facilities. Geneva:
- 410 World Health Organization; 2020 (WHO/2019-nCoV/SARI_treatment_center/2020.1.
- 411 [5] Yang X, Yu Y, Xu J, et al. (2020) Clinical course and outcomes of critically ill
- 412 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
- 413 observational study. Lancet Respir Med. 10.1016/S2213-2600(20)30079-5
- 414 [6] Richardson S, Hirsch JS, Narasimhan M, et al. (2020) Presenting Characteristics,
- 415 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the
- 416 New York City Area. JAMA. 10.1001/jama.2020.6775
- 417 [7] Clinical management of severe acute respiratory infection (SARI) when COVID-19
- 418 disease is suspected. Interim guidance 13 March 2020. WHO/2019-nCoV/clinical/2020.4.
- 419 [8] Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support
- 420 corticosteroid treatment for 2019-nCoV lung injury. The Lancet 395(10223): 473-475.
- 421 10.1016/S0140-6736(20)30317-2

- 422 [9] Zhang W, Zhao Y, Zhang F, et al. (2020) The use of anti-inflammatory drugs in the 423 treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of 424 clinical immunologists from China. Clin Immunol 214: 108393-108393.
- 425 10.1016/j.clim.2020.108393
- 426 [10] Siddiqi HK, Mehra MR COVID-19 Illness in Native and Immunosuppressed States: A
- 427 Clinical-Therapeutic Staging Proposal. The Journal of Heart and Lung Transplantation.
 428 10.1016/j.healun.2020.03.012
- 429 [11] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic
- 430 Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA.
- 431 10.1001/jama.2020.6019
- 432 [12] Xu X, Han M, Li T, et al. (2020) Effective treatment of severe COVID-19 patients
 433 with tocilizumab. ChinaXiv
- 434 [13] Wu C, Chen X, Cai Y, et al. (2020) Risk Factors Associated With Acute Respiratory
- 435 Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in
- 436 Wuhan, China. JAMA internal medicine. 10.1001/jamainternmed.2020.0994
- 437 [14] Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th
- 438 edition). March 4, 2020. Issued by: China National Health Commission.
- 439 [15] (2018) From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital
- 440 Platform Improved Doctors' Work and Patients' Care. AIDS Research and Human
- 441 Retroviruses 34(3): 239-240. 10.1089/aid.2017.0064
- 442 [16] WHO (2020) Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected
- 443 human cases. 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-
- 444 <u>novel-coronavirus-in-suspected-humancases-</u>.
- 445 [17] Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, Di Marco
- 446 F, Gori A, Granata G, Mikulska M, et al: Balancing evidence and frontline experience in the
- 447 early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-

- 448 Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect
- 449 2020. Accepted for publication.
- 450 [18] Cao B, Wang Y, Wen D, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults
- 451 Hospitalized with Severe Covid-19. N Engl J Med. 10.1056/NEJMoa2001282
- 452 [19] Thomas LE, Li F, Pencina MJ (2020) Overlap Weighting: A Propensity Score Method
- 453 That Mimics Attributes of a Randomized Clinical Trial. JAMA. 10.1001/jama.2020.7819
- 454 [20] Guan WJ, Ni ZY, Hu Y, et al. (2020) Clinical Characteristics of Coronavirus Disease
- 455 2019 in China. N Engl J Med. 10.1056/NEJMoa2002032
- 456 [21] Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q (2020) The cytokine release syndrome
- 457 (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may
- 458 be the key to reduce the mortality. International journal of antimicrobial agents: 105954-
- 459 105954. 10.1016/j.ijantimicag.2020.105954
- 460 [22] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in COVID-19:
- 461 A single center experience. J Med Virol. 10.1002/jmv.25801
- 462 [23] Wang D, Hu B, Hu C, et al. (2020) Clinical Characteristics of 138 Hospitalized
- 463 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.
- 464 10.1001/jama.2020.1585
- 465 [24] Fadel R, Morrison AR, Vahia A, et al. (2020) Early Short Course Corticosteroids in
 466 Hospitalized Patients with COVID-19. Clin Infect Dis. 10.1093/cid/ciaa601
- 467 [25] Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due
- to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care
- 469 Med. 10.1007/s00134-020-05991-x
- 470

- 472
- 473

474 Tables

475 **Table 1**

476 Unweighted patients' characteristics stratified for treatment group.

Characteristics	All (n=196)	Tocilizumab/	SOC (n=66)	Standardized
		methylprednisolone/SOC		difference
		(n=130)		
Age, mean (SD); median	67.5 (13.7); 67.9 (32-	64.5 (12.4); 65 (32-91)	73.5 (14.4); 76.2 (39-	0.67
(range)	100)		100)	
Sex (male/female), n (%)	132/64 (67.4/32.7)	91/39 (70/30)	41/25 (62.1/37.9)	0.17
Any comorbidity, n (%)	153 (78.1)	198 (75.4)	55 (83.3)	0.19
Hypertension	77 (39.3)	48 (36.9)	29 (43.9)	
Diabetes	30 (15.3)	22 (16.9)	8 (12.1)	
Cancer	22 (11.2)	15 (11.5)	7 (10.6)	
Obesity	10 (5.1)	8 (6.2)	2 (3.0)	
Ischemic heart failure	22 (11.2)	11 (8.5)	11 (16.7)	
Hospital admission period				
$\leq 11^{\text{th}}$ week of 2020	78 (39.8)	29 (22.3)	49 (74.2)	1.21
12 th week of 2020	66 (33.7)	51 (39.2)	15 (22.7)	0.36
13 th - 14 th week of 2020	52 (26.5)	50 (38.5)	2 (3.1)	0.97
Days from symptoms to	6.8 (4.1); 7 (0-24)	7.5 (4.1); 7 (0-24)	5.6 (4.0); 5 (0-19)	0.47
hospital admission, mean				
(SD); median (range)				
IL-6, mean (SD), median	60.3 (120.3), 36.9 (22-	69.7 (144.8), 40 (27-73)	41.9 (36.1), 31.5 (16-	0.26
(IQR), ng/L	64)		56)	
Ferritin, mean (SD), median	1076 (1060), 762	1251.4 (1194.4), 835	730.2 (596.7), 588	0.55
(IQR), μg/L	(452-1424)	(526-1656)	(316-900)	
CRP, mean (SD), median	100.8 (85.3), 81 (40-	112 (91.3), 90 (45-147)	78.8 (67.2), 65 (30-	0.41
(IQR), mg/L	132)		102)	
D-dimer, mean (SD), median	2340 (4091), 1125	2319 (4441), 1100 (670-	2382 (3327), 1173	0.02

(IQR), µg/L	(665-1730)	1569)	(651-2806)	
PaO ₂ /FiO ₂ , mean (SD),	221 (108), 200 (133-	214.8 (97.8) 199 (134-	232.9 (124.3), 208	0.30
median (IQR), mmHg	289)	277)	(130-308)	
PaO ₂ /FiO ₂ < 100 mmHg	22 (11.2)	13 (10)	9 (13.6)	0.11
PaO ₂ /FiO ₂ < 200 mmHg	93 (47.5)	65 (50)	28 (42.4)	0.15
NIV, n (%)	73 (37.2)	64 (49.2)	9 (13.6)	0.63
Anti-inflammatory treatment				
Steroids only	-	45 (34.6)	-	-
Tocilizumab only	-	29 (22.3)	-	
Combination treatment	-	56 (43.1)		
Number of doses				
tocilizumab				
0		45 (34.6)	-	-
1	-	74 (56.9)	-	-
2	-	11 (8.5)	-	-
Route of administration of				
tocilizumab				
Intravenous	-	49 (57.6)	-	-
Subcutaneous	-	36 (42.4)	-	-
			1	1

477 CRP, C reactive protein; IL-6, interleukin 6; NIV, non invasive ventilation; PaO₂/FiO₂, ratio

478 of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air; SOC,

479 standard of care.

480 **Table 2**

481 Univariable and multivariable analyses of risk factors for failure.

Factors	Univariable		Multivariable	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (1-year change)	1.05 (1.03-1.07)	<0.001	1.05 (1.01-1.07)	<0.001
Sex (male vs. female)	1.91 (1.05-3.45)	0.033	1.77 (0.96-3.25)	0.066
Any comorbidity (Yes vs. No)*	3.85 (1.55-9.60)	0.004		
Treatment period		0.17		
$\leq 11^{\text{th}}$ week of 2020	1.00 (ref)			
12 th week of 2020	0.90 (0.52-1.56)			
13 th - 14 th week of 2020	0.54 (0.27-1.07)			
Time from symptoms (>7 vs	1.01 (0.61-1.67)	0.97		
\leq 7 days)				
IL-6 (1-unit on log-scale)	1.84 (1.45-2.33)	<0.001	1.70 (1.30-2.23)	< 0.001
Ferritin (1-unit on log-scale)	1.10 (0.84-1.44)	0.47		
CRP (1-unit on log-scale)	1.61 (1.21-2.16)	0.001		
D-dimer (1-unit on log scale)	1.50 (1.20 - 1.87)	<0.001		
$PaO_2/FiO_2 < 100 \text{ vs} \ge 100$	3.12 (1.79-5.45)	<0.001	1.95 (1.10-3.46)	0.023
NIV	1.28 (0.78-2.09)	0.33		

⁴⁸²

CRP, C reactive protein; HR: hazard-ratio; IL-6, interleukin 6; NIV, non invasive ventilation;

483 PaO₂/FiO₂, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen

484 inspired air.

- 485 *None of the following single comorbidities resulted significant in multivariable analysis:
- 486 hypertension, diabetes, cancer, obesity, ischemic heart failure, and only ischemic hear disease
- 487 was significant in univariate analysis.

489 **Table 3**

490 OW weighted patients' characteristics stratified for treatment group

Characteristics	Tocilizumab/methilprednisolone/SOC	SOC (n=66)	Standardized
	(n=130)		weighted
			difference
Age, mean (SD);	68.4 (11.7); 68.3 (57.4-77.3)	68.4 (13); 68	0.000
median (IQR)		(59.2-76.9)	
Sex (male/female), n	87/43 (67/33)	44/22 (67/33)	0.000
(%)			
Any comorbidity, n (%)	102 (78.8)	52 (78.8)	0.000
Treatment period			
$\leq 11^{\text{th}}$ week of 2020	68 (52.1)	35 (52.1)	0.000
12 th week of 2020	52 (40.0)	26 (40)	0.000
13 th - 14 th week of 2020	10 (7.9)	5 (7.9)	0.000
Days from symptoms to	7 (3.6); 7 (4-9)	6.8 (4.2); 7 (3-9)	0.071
hospital admission,			
mean (SD); median			
(IQR)			
Il-6, mean (SD); median	45.2 (55.7); 37 (26-51)	45.2 (36.8); 32.4	0.000
(IQR), ng/L		(17-64)	
Ferritin, median (IQR),	901 (671);	901 (727);	0.000
µg/L	762 (491-1095)	706 (479-995)	
PCR, median (IQR),	90.6 (65.3); 73 (43-124)	90.6 (83.3); 63.1	0.000
mg/L		(30-131)	

D-dimer, median (IQR)	1764 (3110); 1080 (680-1500)	1764 (2372);	0.000
		1030 (651-1691)	
PaO ₂ /FiO ₂ , mean (SD);	211.6 (96.1); 196 (144-280)	211.6 (118); 180	0.000
median (IQR), µg/L		(123-291)	
NIV, n (%)	53 (41.1)	27 (41.1)	0.000

NIV, non invasive ventilation; OW: overlap weights; PaO₂/FiO₂, ratio of partial pressure of arterial

oxygen to fractional concentration of oxygen inspired air; SOC, standard of care.

- 492 Table 4
- 493 Clinical and demographic characteristics in treated patients included in outcome analyses

Characteristics	Methylprednisolone	Tocilizumab	Combined
	(n=45)	(n=29)	(n=56)
Age, mean (SD); median (range)	67.5 (13.9); 68.2	65.9 (10.2);	61 (11.7); 63
	(37-91)	67.4 (42-80)	(32-85)
Sex (male/female), n (%)	32/13 (71.1/28.9)	24/5 (82.8/17.2)	35/21
			(62.5/37.5)
Any comorbidity, n (%)	36 (80)	23 (79.3)	39 (69.6)
Treatment period			
$\leq 11^{\text{th}}$ week of 2020	4 (8.9)	22 (75.8)	3 (5.4)
12 th week of 2020	30 (66.7)	6 (20.7)	15 (26.8)
13 th - 14 th week of 2020	11 (24.4)	1 (3.5)	38 (67.9)
Days from symptoms to hospital	7.2 (4.7); 7 (0-21)	7.7 (3.5); 8 (1-	7.6 (3.8); 7 (2-
admission, mean (SD); median		15)	24)
(range)			
IL-6, median (IQR), ng/L	40 (22-68)	45 (33-88)	37 (27-63)
Ferritin, median (IQR), µg/L	741 (380-1087)	1422 (845-	760 (444-
		1846)	1858)
CRP, median (IQR), mg/L	82 (43-124)	121 (52-218)	88 (44-153)
D-dimer, median (IQR), µg/L	1080 (730-1600)	1280 (950-	1055 (618-
		2500)	1411)
PaO ₂ /FiO ₂ , median (IQR), mmHg	201 (156-311)	203 (144-280)	190 (125-254)
PaO ₂ /FiO ₂ < 100 mmHg	6 (13.3)	1 (3.5)	6 (10.7)
PaO ₂ /FiO ₂ < 200 mmHg	22 (48.9)	13 (44.8)	30 (53.6)

NIV, n (%)	20 (44.4)	13 (44.8)	31 (55.4)
Number of doses tocilizumab			
0		-	-
1		22 (75.9)	54 (96.4)
2		7 (24.1)	2 (3.6)
Route of administration of			
tocilizumab			
Intravenous		18 (62.1)	31 (55.4)
Subcutaneous		11 (37.9)	25 (44.6)

494 CRP, C reactive protein; IL-6, interleukin 6; NIV, non invasive ventilation; PaO₂/FiO₂, ratio

495 of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air.

497 Table 5

- 498 Univariable and multivariable analyses for risk factors of failure endpoint in patients treated with
- 499 tocilizumab and/or methylprednisolone and standard of care (SOC).

Factors	Univariable		Multivariable		
	HR (95% CI)	p-value	HR (95% CI)	p-value	
Treatment		0.17		0.45	
Methylprednisolone	1.00 (ref)		1.00 (ref)		
Tocilizumab	0.69 (0.27-1.81)		0.65 (0.23-1.82)		
Combined	0.45 (0.19-1.06)		0.59 (0.24-1.43)		
Age (1-year change)	1.05 (1.02-1.09)	0.002	1.05 (1.01-1.09)	0.012	
Sex (male vs. female)	1.68 (0.68-4.14)	0.26	1.54 (0.61-3.91)	0.37	
Any comorbidity (Yes vs.	4.76 (1.13-20.04)	0.034	-		
No)					
Treatment period		0.46			
$\leq 11^{\text{th}}$ week of 2020	1.00 (ref)		-		
12 th week of 2020	1.03 (0.41-2.59)		-		
13 th - 14 th week of 2020	0.62 (0.22-1.70)		-		
Time from symptoms (>7	0.93 (0.44-1.98)	0.86	-		
$vs \le 7 days$)					
Il-6 (1-unit on log-scale)	1.93 (1.38-2.70)	< 0.001	1.87 (1.29-2.71)	0.001	
Ferritin (1-unit on log-	1.20 (0.78-1.83)	0.41	-		
scale)					

1.02-2.57) 0.04	-	
1.19 - 2.21) 0.002	-	
1.09-6.66) 0.032	1.88 (0.72-4.70)	0.14
0.90-4.40) 0.090	-	
	(1.19 - 2.21) 0.002 (1.09-6.66) 0.032	(1.19 - 2.21) 0.002 - (1.09-6.66) 0.032 1.88 (0.72-4.70)


502 CRP, C reactive protein; HR: hazard-ratio; IL-6, interleukin 6; NIV, non invasive ventilation;

504 inspired air.


⁵⁰³ PaO₂/FiO₂, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen

505	Figure	legends


- 506 Figure 1
- 507 The flowchart of the included patients.
- 508
- 509 Figure 2
- 510 Adjusted failure-free (intubation or death) survival in patients who received tocilizumab
- 511 and/or methylprednisolone and standard of care (SOC) vs. SOC.
- 512
- 513 Figure 3
- 514 Adjusted failure-free survival in patients receiving anti-inflammatory treatment: tocilizumab
- 515 only, methylprednisolone only, and combined treatment.
- 516
- 517 Figure 4
- 518 Adjusted overall survival in patients who received tocilizumab and/or methylprednisolone and
- 519 standard of care (SOC) vs. SOC.
- 520



* These two groups were included in the main landmark analysis




SOC



Tocilizumab Combined

Steroids

23 23 56 56 56 54 51 50 49 46 46 46 46 45 45 45 45 45 45 45 45 45



SOC

SOC